A sibling cord blood (CB) transplantation was performed in a boy with Wiskott-Aldrich syndrome. The CB (31 × 10 6 CD34 + cells) derived from a newborn sister with neonatal alloimmune thrombocytopenia (NAIT) with 40 000 platelets/l, caused by a maternal anti-HPA-5b and HLA-A2 antibody. Maternal serum did not inhibit clonogenicity after in vitro testing of megakaryopoiesis. Accordingly, this CB was accepted for sibling transplantation. The transplantation showed a good course with fast and sustained hematopoietic reconstitution (granulocytes Ͼ500/l on day +16, platelets Ͼ50 000/l on day +30). This case demonstrates a successful CB transplantation from a donor suffering from NAIT. Bone Marrow Transplantation (2001) 28, 803-806.
It is well known that irregular maternal red blood cell antibodies may cause hemolytic disease of the newborn (HDN) just as maternal platelet-specific antibodies often lead to neonatal alloimmune thrombocytopenia (NAIT) during pregnancy. Recently, it was demonstrated that red blood cell anti-Kell antibodies strongly inhibit the growth of cord blood (CB) erythroid and megakaryocytic progenitor cells. 1, 2 An inhibitory effect was also shown for plateletspecific antibodies on in vitro megakaryocyte growth. 3 It is known that the platelet glycoprotein complex IIb/IIIa is expressed on different lineages of fetal progenitor cells and is involved in regulation of hematopoiesis. 4, 5 The expression of other platelet glycoprotein complexes on different progenitor cell subsets has not been investigated in such detail. The expression of ␣2␤1 integrins with the subunit of the very late antigen 2 (VLA-2) (corresponding to the glycoprotein complex Ia/IIa) is mainly restricted to megakaryocytic progenitors. 6, 7 On the other hand, pluripotent hematopoietic cell lines, eg K562, demonstrate megakaryocytic properties including increased surface expression of ␣2␤1 integrins. 8 Finally, it was recently proved that these ␣2␤1 integrins are expressed by human megakaryocytes at an early stage of maturation. 9 These studies lead to the question, whether antibodies with specificity for this glycoprotein complex would have an influence on hematopoiesis. Here, we present experimental and clinical data about the influence of platelet glycoprotein Ia/IIa antibodies on platelet recovery and engraftment after allogeneic CB transplantation from a sibling suffering from NAIT.
Materials and methods

Patient
A 7-year-old boy with clinically progressive Wiskott-Aldrich syndrome (WAS) was diagnosed in 1997. The patient showed consistent thrombocytopenia (Ͻ20 × 10 9 /l), signs of T and B cell deficiency and frequent infections, mainly manifested as otitis media or bronchitis. Since other compatible donors were not available, CB was collected for an allogeneic transplantation from a sibling born in May 1998.
Collection and processing of CB
The pregnancy was uncomplicated. A cesarean section was performed at term due to signs of fetal distress in active labor. The female neonate was in good condition. She had a birth weight of 3800 g and a slight hypoglycemia due to maternal gestational diabetes. Immediately after delivery, 55 ml CB were collected into a citrate-containing closed bag system under sterile conditions. The leukocytes at birth were 30 300/l (confirmed by identical results from automated and manual microscopic counting). Neither infection nor other endogenous diseases could be verified. The hemoglobin was 10.8 g/dl and the red blood cell count was 3.68 × 10 6 /l. The CB was prepared according to the German guidelines for the collection and processing of cord blood. 10 The unmanipulated CB was processed within 24 h after collection (10% DMSO) and stored in the vapour phase of liquid nitrogen.
Flow cytometric quantitation of CD34 + cells before cryopreservation resulted in a total of 31 × 10 6 CD34 + cells (corresponding to 1.55 × 10 6 CD34 + cells/kg recipient body weight) with a viability of 83% after cryopreservation (aliquot from pilot tube). Clonogenic assays resulted in a total of 24 × 10 4 CFU-GM and 160 × 10 4 BFU-E. The total nucleated cell (TNC) count was 1.20 × 10 8 /kg recipient body weight.
Diagnosis of NAIT
At the time of delivery, the newborn sister was thrombocytopenic (40 000 platelets/l). The thrombocytopenia persisted for 3 days. A platelet-specific glycoprotein complex Ia/IIa antibody (anti-HPA-5b) and an anti-HLA-A2 antibody were detected by testing maternal serum against paternal cells and against a defined panel of cells. The platelet-specific antibody was detected using the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay. 11 
Platelet genotyping
Genetic typing of polymorphisms of the HPA1-5 system was performed with SSP ('Domino System HPA'; Protrans, Ketsch, Germany). The typing gave conclusive results for the CB donor (HPA5a/b), the recipient (HPA5a/5b), the mother (HPA-5a/a) and father (HPA-5a/b).
Megakaryopoiesis
Megakaryopoietic progenitors were quantified using the MegaCult-C kit (Stem Cell Technologies, Vancouver, Canada). In brief, after thawing and washing, the CB aliquot was adjusted to 200 000 cells/ml serum-free medium containing recombinant cytokines. The native maternal serum was stored at 6°C for 24 h before use. As previously described, 20% (200 l) antibody-containing maternal serum (or antibody-free control serum) were added per ml sample. 12 Before further manipulations, the samples were at first incubated at 37°C and 5% CO 2 for 2 h. Then, after addition of 1.2 ml collagen solution, aliquots of 0.75 ml were pipetted into two-double chamber slides. The chambers were incubated for 12 days at 37°C and 5% CO 2 . After that, the CFU were fixed on a polypropylene membrane. The CFU-megakaryocytes (CFU-Mk) were counted after immunochemical staining with an antibody directed against the glycoprotein complex IIb/IIIa present on megakaryocytes. A secondary staining and a nuclear counterstain allowed the differentiation of pure Mk, mixed Mk and nonMk colonies. 12 Six replicate determinations were performed and the mean numbers of CFU were calculated.
Thawing of CB
The cryopreserved CB transplant was thawed according to the New York Blood Bank protocol. 13 The cryoprotectant (10% DMSO) was removed by centrifugation and a subsequent washing procedure. Quantitation of CD34 + cells after cryopreservation resulted in 1.59 × 10 6 CD34 + cells/kg recipient body weight (recovery 103%) and 7.13 × 10 7 total nucleated cell (TNC) /kg recipient body weight (recovery 59%). Sterility testing of the CB was negative. Figure 1 demonstrates the numbers of megakaryocytic progenitors. A mean of 39.7 (Ϯ12.8) CFU-Mk/l CB were detected in the absence of maternal serum vs 49.3 (Ϯ26.5) CFU-Mk/l CB with maternal serum. This difference was not statistically significant (P = 0.36, Mann-Whitney test). Accordingly, the CB was released for sibling transplantation at the pediatric transplantation unit (Charité of the Humboldt-University in Berlin) on 31 May 1999. The patient received busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) as conditioning and cyclosporin A as GVHD prophylaxis. The CB was well tolerated after transplantation.
Results
The patient showed a fast hematopoietic reconstitution (granulocytes at day +16 Ͼ500/l and at day +17 Ͼ 1000/l). The platelets rose above 50 000/l at day +30. The patient was released from the transplant unit after 5 weeks in good condition with 100 000 platelets/l. Flow cytometric immunophenotyping in the period following transplantation demonstrated a continuous increase of T and B lymphocytes. Table 1 demonstrates the cell counts after CB transplantation.
Chimerism analysis performed by fluorescence in situ hybridization (FISH) technique showed 96% donor karyo- type 30 days after transplantation. An acute GVHD (grade I) was diagnosed and treated with prednisone at day 40 after transplantation and disappeared rapidly.
Discussion
This is the first reported cord blood transplantation with a donor suffering from NAIT. In this case, a maternal HPA5b antibody specific for the glycoprotein complex Ia/IIa and an HLA-A2 antibody were detected and had caused thrombocytopenia in the stem cell donor but did not clinically affect hematopoiesis after stem cell transplantation. We did not expect that the HLA-A2 antibody would have a severe clinical effect on the transplant, since the determination of maternal HLA antibodies is rarely associated with NAIT and with the presence of HLA antibodies in cord blood samples. 14 In contrast, it is known that HPA-5b antibodies may cause severe courses of NAIT with fatal clinical consequences. 15 The maternal HPA-5b antibody led to a distinct thrombocytopenia of the newborn cord blood stem cell donor, indicating that a significant concentration of antibodies has passed the placenta and was bound to target cells.
We were not able to investigate further the binding kinetics of the maternal HPA-5b antibody to the glycoprotein complex Ia/IIa of different CB cell fractions, since additional CB aliquots were not available at a later stage after CB collection. However, the functional in vitro testing of progenitor cells in the presence and absence of maternal antibody-containing serum and the clinical course after transplantation demonstrate that the CB from this donor with NAIT was capable of supporting megakaryopoiesis and led to a fast and sustained platelet recovery.
The total volume of this transplanted CB was not very great (55 ml), although the number of progenitor cells (31 × 10 6 CD34 + cells) resulted in a high above-average yield. Other groups reported mean collection volumes between 33.2 and 174.4 ml CB, but it should be noticed that procedures for collection, dilution and anticoagulation of CB are not standardized and the volumes are therefore not directly comparable. [16] [17] [18] In contrast, the mean numbers of progenitor cells in CB transplants of the above-mentioned studies ranged from 1.74 to 4.4 × 10 6 CD34 + cells/unit and were therefore distinctly lower than in our sample.
After thawing and before transplantation, the CB was washed according to the New York Blood Bank protocol. This procedure reduces the amount of cryoprotectant Bone Marrow Transplantation (DMSO) and plasma. We would not expect a significant change in the kinetics of potentially cell-bound antibodies caused by the washing procedure. However, a final conclusion cannot be drawn, since we have not investigated the influence of this washing procedure on the affinity of platelet-specific antibodies to progenitor cell molecules.
Studies focused on hematopoietic reconstitution after allogeneic CB transplantations reported median platelet engraftment times of 84, 94, 75 and 60-139 days with platelet levels of Ͼ50 000/l, respectively. [19] [20] [21] The platelet recovery time of 30 days with identical platelet levels (Ͼ50 000/l) in this case was very fast. Therefore, from the clinical point of view, one may conclude that megakaryopoiesis and platelet recovery were normal after this CB transplantation.
Accordingly, at least some platelet-specific antibodies (such as anti-HPA-5b) may be acceptable in stem cell transplantation, even if corresponding antigens are expressed on progenitor cells and such antibodies have clinically caused thrombocytopenia.
